	US 11,918,660 B2
	Viral vectors for cancer therapy
Suma Krishnan, Pittsburgh, PA (US); Trevor Parry, San Diego, CA (US); Dana Michelle Previte, Sewickley, PA (US); and Mary Jane Duermeyer, Glenshaw, PA (US)
Assigned to Krystal Biotech, Inc., Pittsburgh, PA (US)
Filed by Krystal Biotech, Inc., Pittsburgh, PA (US)
Filed on Mar. 8, 2023, as Appl. No. 18/180,791.
Application 18/180,791 is a continuation of application No. 17/711,947, filed on Apr. 1, 2022, granted, now 11,779,660.
Claims priority of provisional application 63/170,103, filed on Apr. 2, 2021.
Prior Publication US 2023/0241251 A1, Aug. 3, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/869 (2006.01); A61K 35/763 (2015.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C12N 7/00 (2006.01); C12N 15/24 (2006.01); C12N 15/26 (2006.01); C12N 15/86 (2006.01)

CPC A61K 48/0066 (2013.01) [A61K 38/193 (2013.01); A61K 38/2013 (2013.01); A61K 38/208 (2013.01); A61P 35/00 (2018.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); C12N 2710/16622 (2013.01); C12N 2710/16633 (2013.01); C12N 2710/16643 (2013.01); C12N 2710/16662 (2013.01); C12N 2710/16671 (2013.01)]

23 Claims

1. A pharmaceutical composition comprising:

(a) a herpes simplex virus type 1 (HSV-1) comprising a recombinant HSV-1 genome, wherein the recombinant HSV-1 genome comprises a polynucleotide encoding an Interleukin (IL)-2 polypeptide and a polynucleotide encoding an IL-12 polypeptide; and

(b) a pharmaceutically acceptable excipient,

wherein the IL-12 polypeptide comprises an IL-12 subunit alpha polypeptide and an IL-12 subunit beta polypeptide connected by a linker polypeptide, and

wherein the recombinant HSV-1 genome further comprises a first promoter operably linked to the polynucleotide encoding the IL-2 polypeptide and a second promoter operably linked to the polynucleotide encoding the IL-12 polypeptide.